Collaborations

DirectDesign Discovery collaboration inked with KAI Pharmaceuticals

Published in Proteomics Weekly, November 14th, 2005

Eidogen-Sertanty, Inc., a San Diego, California-based computational drug-discovery solutions provider, announced that they have engaged in a collaborative service project with KAI Pharmaceuticals, a South San Francisco, California-based drug-discovery company focused on the development of Protein Kinase C (PKC) modulators.

Under the terms of the service arrangement, Eidogen-Sertanty will utilize the Target Informatics Platform (TIP) and EVE Comparative Visualization software within its DirectDesign Discovery Service to perform extensive structural characterization and comparative binding site analysis for PKC regulatory domains. The collaborative project will allow KAI...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2005-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry